Track record · closed signal

Halozyme Therapeutics Inc (HALO) — closed signal from May 5, 2026

Target reached Published before the outcome was known, scored automatically when the window closed on August 3, 2026 — +27.2% at the close.

Predicted vs. what happened

HALO price · publication thesis → realized outcomesplit-adjusted

$62.50 – $65.50Entry zone — fair-value band

$64.70Published — price the day we called it

$77.64Target — the price the thesis aimed for

$84.44Peak — highest point inside the window, not a realized return

$82.27Window close — end-of-window price, context only

What happened

Target reached

Reached its target in 56 days.

At window close

+27.2%

realized, from the publication price to the last close inside the window

Peak gain

+30.5%

peak, from the publication price — not a realized return

S&P 500, same window

+5%

SPY over the identical days, dividend-adjusted

Window close

$82.27

last close inside the window, ended August 3, 2026

Peak price

$84.44

peak on July 28, 2026 — not a realized return

Days to target

The thesis — published May 5, 2026

Predicted growth

+20%

over the measurement window

Target price

$77.64

the price the thesis aimed for

Entry zone

$62.50 – $65.50

the fair-value band we waited for

Price at publication

$64.70

published May 5, 2026

Confidence

68%

how strongly the data lined up

Timeframe

Short-term (0–3 months)

Halozyme earns from partnerships and royalties and recent announcements support the idea royalties will keep growing. A new CFO from a large drug company adds credibility. Near-term quarterly results give a chance for good news, but company debt and insider stock selling make the short-term outlook cautious rather than strongly bullish.

Primary drivers

Growing royalty income from partner drug sales is a core revenue source
Experienced CFO improves confidence in execution and finances
Quarterly results are a near-term event that could move the story
Partnering platform creates repeatable revenue opportunities over time

How it played out

HALO: target reached in 56 days

Lyra published a short-term thesis for 20% growth from $64.70 to $77.64. The thesis pointed to growing royalty income, repeatable partner revenue, an experienced new CFO, and quarterly results as a near-term event. It also flagged debt and insider selling, so the outlook was cautious.

The shares reached $77.64 in 56 days. They later peaked at $84.44 on July 28, a 30.5% gain, and ended the window at $82.27. The target was reached and the peak exceeded it. The published thesis played out.

What happened during the window

On May 6, 2026, Halozyme and Oruka announced a global licensing agreement covering ORKA-001 and one additional target. On May 11, Halozyme reported first-quarter revenue of $376.7 million and royalty revenue of $240.7 million, then reiterated its 2026 guidance.

Prices are shown split- and dividend-adjusted, matching what public charts show today.

Lyra

Read the next call before it closes.

This is one signal, scored after the fact. Today’s picks come with the same plain-language thesis — published before anyone knows the outcome.

See today’s picks All HALO signals